Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
Status:
Recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
This pilot study is evaluating how well pembrolizumab and combination chemotherapy before
surgery work for the treatment of specific types of muscle-invasive bladder cancer that have
unusual appearance (variants). Immunotherapy with monoclonal antibodies, such as
pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as
methotrexate, vinblastine, adriamycin, and cisplatin work in different ways to stop the
growth of tumor cells, either by killing the cells, by stopping them from dividing, or by
stopping them from spreading. Giving pembrolizumab and combination chemotherapy before
surgery may work better in treating patients with these muscle invasive bladder cancer
variants compared to chemotherapy alone.
Phase:
Phase 2
Details
Lead Sponsor:
University of Washington
Collaborators:
Merck Sharp & Dohme Corp. National Cancer Institute (NCI)